Suppr超能文献

odanacatib 治疗对绝经后妇女股骨的小梁骨和皮质骨有影响:为期两年的安慰剂对照试验结果。

Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women: results of a two-year placebo-controlled trial.

机构信息

Synarc Inc., Hamburg, Germany; Institute of Medical Physics, University of Erlangen, Erlangen, Germany.

出版信息

J Bone Miner Res. 2015 Jan;30(1):30-8. doi: 10.1002/jbmr.2292.

Abstract

Odanacatib, a selective cathepsin K inhibitor, increases areal bone mineral density (aBMD) at the spine and hip of postmenopausal women. To gain additional insight into the effects on trabecular and cortical bone, we analyzed quantitative computed tomography (QCT) data of postmenopausal women treated with odanacatib using Medical Image Analysis Framework (MIAF; Institute of Medical Physics, University of Erlangen, Erlangen, Germany). This international, randomized, double-blind, placebo-controlled, 2-year, phase 3 trial enrolled 214 postmenopausal women (mean age 64 years) with low aBMD. Subjects were randomized to odanacatib 50 mg weekly (ODN) or placebo (PBO); all participants received calcium and vitamin D. Hip QCT scans at 24 months were available for 158 women (ODN: n = 78 women; PBO: n = 80 women). There were consistent and significant differential treatment effects (ODN-PBO) for total hip integral (5.4%), trabecular volumetric BMD (vBMD) (12.2%), and cortical vBMD (2.5%) at 24 months. There was no significant differential treatment effect on integral bone volume. Results for bone mineral content (BMC) closely matched those for vBMD for integral and trabecular compartments. However, with small but mostly significant differential increases in cortical volume (1.0% to 1.3%) and thickness (1.4% to 1.9%), the percentage cortical BMC increases were numerically larger than those of vBMD. With a total hip BMC differential treatment effect (ODN-PBO) of nearly 1000 mg, the proportions of BMC attributed to cortical gain were 45%, 44%, 52%, and 40% for the total, neck, trochanter, and intertrochanter subregions, respectively. In postmenopausal women treated for 2 years, odanacatib improved integral, trabecular, and cortical vBMD and BMC at all femur regions relative to placebo when assessed by MIAF. Cortical volume and thickness increased significantly in all regions except the femoral neck. The increase in cortical volume and BMC paralleled the increase in cortical vBMD, demonstrating a consistent effect of ODN on cortical bone. Approximately one-half of the absolute BMC gain occurred in cortical bone.

摘要

odanacatib 是一种选择性组织蛋白酶 K 抑制剂,可增加绝经后妇女的脊柱和髋部的骨面积密度(aBMD)。为了更深入地了解对小梁骨和皮质骨的影响,我们使用 Medical Image Analysis Framework(MIAF;德国埃尔朗根大学医学物理研究所)分析了接受 odanacatib 治疗的绝经后妇女的定量计算机断层扫描(QCT)数据。这项国际、随机、双盲、安慰剂对照、为期 2 年、3 期临床试验纳入了 214 名低骨密度的绝经后妇女(平均年龄 64 岁)。受试者被随机分配至 odanacatib 50mg 每周(ODN)或安慰剂(PBO);所有参与者均接受钙和维生素 D 治疗。24 个月时,158 名女性(ODN:n=78 名女性;PBO:n=80 名女性)可进行髋部 QCT 扫描。24 个月时,总髋部积分(5.4%)、小梁体积 BMD(vBMD)(12.2%)和皮质 vBMD(2.5%)存在一致且显著的治疗差异(ODN-PBO)。整体骨量无显著的治疗差异。骨矿物质含量(BMC)的结果与积分和小梁容积的 vBMD 结果非常匹配。然而,由于皮质体积(1.0%至 1.3%)和厚度(1.4%至 1.9%)的小但大部分显著增加,皮质 BMC 的增加百分比在数值上大于 vBMD 的增加百分比。由于总髋部 BMC 的治疗差异(ODN-PBO)接近 1000mg,皮质骨增加的 BMC 比例分别为 45%、44%、52%和 40%,用于总髋部、颈部、转子间区和转子下区。在接受 2 年治疗的绝经后妇女中,与安慰剂相比,odanacatib 通过 MIAF 改善了所有股骨区域的总积分、小梁和皮质 vBMD 和 BMC。除股骨颈外,所有区域的皮质体积和厚度均显著增加。皮质体积和 BMC 的增加与皮质 vBMD 的增加平行,表明 ODN 对皮质骨的一致作用。绝对 BMC 增加的大约一半发生在皮质骨中。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验